High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

Systemic amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder caused by the extracellular deposition of misfolded immunoglobulin light chains as protein fibrils in tissues. This leads to vital organ damage. It is incurable and has a relapsing–remitting course. With a lack of approved treatments at relapse, therapies for relapsed multiple myeloma are used in AL amyloidosis. However, this may be challenging due to underlying organ dysfunction, most commonly cardiac and renal impairment. Most data are from the use of immunomodulatory agents and, lately, daratumumab. Options for patients who relapse after daratumumab in AL amyloidosis remain unclear.